Observational studyCancer2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.
Francesca Palandri et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this paperpooled itcites it